Researchers May Be Closer To Finding A Way To Reverse Effects Of Apixaban.

MedPage Today  (6/22, Kaiser) reports, "Researchers may be closer to finding a way to reverse the effects of the novel oral anticoagulant apixaban, a factor Xa inhibitor, according to results presented in the American Heart Association's Emerging Science Series webinar." Investigators found, "using healthy donor blood...that prothrombin complex concentrates (PCCs) and activated prothrombin complex concentrates (aPCCs) better restored thrombin generation than recombinant factor VII." However, "recombinant factor VII was better at improving clotting time and clot firmness, followed by aPCC and PCC."